Media coverage about ContraVir Pharmaceuticals (NASDAQ:CTRV) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.4570631060272 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern’s rankings:

A number of analysts have commented on CTRV shares. Maxim Group set a $4.00 target price on ContraVir Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. ValuEngine raised ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

ContraVir Pharmaceuticals (NASDAQ CTRV) traded down $0.03 during trading on Tuesday, hitting $0.26. The company’s stock had a trading volume of 2,380,000 shares, compared to its average volume of 958,524. The company has a market cap of $20.67, a price-to-earnings ratio of -1.10 and a beta of 1.11. ContraVir Pharmaceuticals has a twelve month low of $0.23 and a twelve month high of $1.96.

ILLEGAL ACTIVITY NOTICE: “ContraVir Pharmaceuticals (CTRV) Earns Coverage Optimism Rating of 0.04” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Insider Buying and Selling by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.